EBD Group is part of the Knowledge and Networking Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Key Sessions

Alex Lash

Innovation in an uncertain world

Xconomy

07:45 18:00 (615 mins)

Main agenda

Registration

Level 0, Entrance Hall

07:45 10:30 (165 mins)

Main agenda

Continental Breakfast

Level 0, Exhibit Hall

07:45 18:00 (615 mins)

Main agenda

Exhibition open

Level 0, Exhibit Hall

09:00 10:30 (90 mins)

Main agenda

Clinical trials in early stage oncology development

Location: Level 1, Room 119

The mobilization of large patient populations for clinical trials will always be a difficult undertaking for biotech companies operating on their own. From financing to key opinion leader access, technical expertise to patient recruitment, partnerships are a key part in making a success of clinical trials. As personalized medicine plays an increasingly important role in oncology trials especially, the mobilizing power of large-scale hospital research networks can contribute a decisive ingredient to success. The resources, technical expertise and efficiencies that such collaborations provide, perhaps most importantly for early stage trials, contribute not only to scientific success but also to strategic collaboration potential at later stages. Join this workshop to learn how partnerships in early stage oncology trials can ease the crunch points of development and how early stage trials can give biotech companies an edge in both clinical development and company strategy.

  • Moderator Edward Garmey - Partner and Oncology Drug Development Consultant, Alacrita Consulting
  • Panelist Carlos López - Business Development Manager, Vall d'Hebron Institute of Oncology
  • Panelist Sonal Patel - VP, Oncology Scientific Innovation, Johnson & Johnson Innovation
  • Panelist Gemma Sala - Head, Clinical Trials Office for Phase I Trials, Vall d'Hebron Institute of Oncology/Barcelona Clinical Trials Platform
  • Panelist Robert Wasserman - Chief Medical Officer, Northern Biologics
  • Panelist Tamara Maes - CSO, Oryzon

09:00 10:30 (90 mins)

Main agenda

Strategy, planning and partnerships: Managing the drug development lifecycle

Location: Level 1, Room 121

In the increasingly virtual and complex world of pharma R&D, successful drug development requires careful planning and collaborative effort. Each phase presents a unique set of issues and requires a different mix of partners and support. This panel will address some of the key challenges in integrated drug development, identifying the range of internal and external partners that need to be involved, and learning when and how to do so to achieve the most positive commercial outcome.

  • Moderator Ann Baker - VP, Life Sciences Practice, Charles River Associates
  • Panelist Stuart Collinson - CEO, Tioga Pharmaceuticals and Partner, Forward Ventures
  • Panelist Elena Erroba - Business Development Director, 3P BioPharma
  • Panelist Emma Gasol - Business Development Director In-Licensing, Laboratorios Gebro Pharma
  • Panelist Kevin Lynch - VP, Search and Evaluation, AbbVie

09:00 10:30 (90 mins)

Main agenda

Changing administration, changing policy

Location: Level 1, Room 123

Change and uncertainty go hand in hand with opportunity and possibility. This discussion will examine the practical implications of doing business in changing times.

  • Moderator Leora Schiff - Principal, Altius Strategy Consulting
  • Panelist Joseph Damond - Senior VP, International Affairs, Biotechnology Innovation Organization (BIO)
  • Panelist Barbara Freischem - Executive Director, EBE
  • Panelist Ronald Jager - Director Healthcare Biotechnology, EuropaBio
  • Panelist Bernd Mühlenweg - Chief Business Officer, Nanobiotix
  • Panelist Morrie Ruffin - Managing Partner, Adjuvant Partners

10:00 18:30 (510 mins)

Main agenda

One-to-one Meetings

10:45 11:15 (30 mins)

Main agenda

Welcome

Location: Level 1, Room 112

  • Speaker Anna Chrisman - Group Managing Director, EBD Group
  • Speaker David Thomas - Senior Director, Industry Research and Analysis, Biotechnology Innovation Organization (BIO)
  • Speaker Albert Barberà - CEO, BIOCAT
  • Speaker Jordi Baiget i Cantons - Minister for Business and Knowledge, Government of Catalonia

11:15 12:30 (75 mins)

Main agenda

Innovation in an uncertain world

Location: Level 1, Room 112

In the best of times, biotech innovation is full of uncertainty. But today's political, regulatory, and social upheaval have added more complexity than usual. How are cutting-edge biotech companies trying to compete in a global marketplace dealing with drug-price anger, science skepticism, and policies to close borders and protect jobs? We will discuss these issues and more.

  • Moderator Alex Lash - National Biotechnology Editor, Xconomy
  • Panelist Annie De Groot - CEO and CSO, EpiVax
  • Panelist Ji Li - Executive VP and Global Head of Business Development, BeiGene
  • Panelist Kevin Sin - VP, Oncology Business Development, Genentech Partnering

12:00 14:00 (120 mins)

Main agenda

Luncheon

Level 0 – Exhibit Hall

Level 2 – Banquet Hall

13:30 15:00 (90 mins)

Main agenda

Developing winning presentations

Location: Level 1, Room 131

A short buzz training session delivered by EBD Academy 

Overview

This concise workshop created by EBD Academy has been designed to provide participants with practical tools, skills and ideas that can be implemented immediately at the partnering event. After attending, delegates will have the toolkit to develop presentations that will engage with the audience and lead to successful deals and partnerships. Take away a diamond relationship top tip guide to help you in future partnering situations.

Course breakdown

 Tuning In       

  • Audience Analysis toolkit        
  • What do they want and need?        
  • What’s keeping them up at night?

What’s Your Point?        

  • Choosing your strategy - Influence or Educate?        
  • Preparing your key purpose       
  •  If they remember nothing else what is it you want them to take away?

Influential Packaging         

  • Structuring for impact        
  • A powerful plan to reinforce the key messages     
  • Mixing the 4 types of content

What is a Buzz session?

Delivered by EBD Academy and developed in partnership with EBD Group – buzz sessions will provide attendees with take-away skills and knowledge that will benefit them while at the event and in their professional careers. All buzz sessions are designed to be concise, informative and engaging which creates a learning environment that is exciting to be a part of. 

Benefits of attending a Buzz session•        

  • Gain practical skills that can be implemented immediately at the EBD event       
  • High intensity sessions designed to improve your skillset       
  • Interactive - Learn from the expert and others attending the session        
  • Concise and informative
  • Speaker Simon Fagg - Buzz Session Expert, EBD Academy

15:00 16:30 (90 mins)

Main agenda

Diamond relationships for successful partnering

Location: Level 1, Room 131

A short buzz training session delivered by EBD Academy 

Overview 

This concise workshop created by EBD Academy has been designed to provide participants with practical tools, skills and ideas that can be implemented immediately at the partnering event. After attending, delegates will have gained skills in establishing and maintaining diamond relationships that lead to successful long term partnerships. Take away a diamond relationship top tip guide to help you in future partnering situations.

Course breakdown 

Building Diamond Relationships        

  • Why a diamond?       
  • Connecting the key people together       
  • Stakeholder mapping

Projecting Credibility  

  • Credibility barriers and enhancers   
  • Quickly establishing authenticity and integrity        
  • Dealing with nervous energy        
  • Laying foundations for the long-term

Understanding and Adaptability        

  • High impact questions        
  • Focus on outcomes        
  • Asking the unasked questions       
  • Establishing the decision making process

What is a Buzz session?

Delivered by EBD Academy and developed in partnership with EBD Group – buzz sessions will provide attendees with take-away skills and knowledge that will benefit them while at the event and in their professional careers. All buzz sessions are designed to be concise, informative and engaging which creates a learning environment that is exciting to be a part of. 

Benefits of attending a Buzz session        

  • Gain practical skills that can be implemented immediately at the EBD event        
  • High intensity sessions designed to improve your skillset        
  • Interactive - Learn from the expert and others attending the session         
  • Concise and informative
  • Speaker Simon Fagg - Buzz Session Expert, EBD Academy

13:30 14:30 (60 mins)

Main agenda

Diversifying risk with a portfolio strategy

Location: Level 1, Room 123

Pipeline management for both biotech and pharma companies can be a complicated process. One method that can yield surprising results is a portfolio approach that allows resources to be channeled to those therapies most likely to succeed: for example, increased specialization among big pharma, or companies revisiting or repurposing products that thus far have been dormant. This panel will examine a number of portfolio approaches that can bring to the surface forgotten possibilities, reduce risk and help companies identify the strengths they can bring to the partnering table.

  • Moderator Neel Patel - Managing Director, inVentiv Health Consulting
  • Panelist Rick Davis - Senior Director, New Ventures and Transactions, Oncology, Johnson & Johnson Innovation
  • Panelist Lubor Gaal - Head, External Innovation and Licensing, Almirall
  • Panelist Jennifer Laird - Senior Director, Neuroscience, Eli Lilly
  • Panelist Giles Nobecourt - Partner, Edmond de Rothschild Investment Partners
  • Panelist Carlos R. Plata Salamán - CSO, CMO and Head of R&D, Esteve

14:45 15:45 (60 mins)

Main agenda

Working with alternative investors

Location: Level 1, Room 123

As the spectrum of funding sources widens to include disease-specific foundations, funds, and angel investors, how is a biotech company to navigate these new waters? While the primacy of VCs when it comes to funding is hardly a question, how do the dynamics between the traditional and alternative funding sources change the relationship between funder and company, funder and funder? What impacts could funding sources today have on partnering possibilities in the future?

  • Moderator Raul Martin-Ruiz - Principal, Ysios Capital
  • Panelist Carolyn Green - Executive Director, Strategic Investments, Pfizer Worldwide R&D, ERDI
  • Panelist Marc Lemonnier - CEO, Antabio
  • Panelist Daniel Oliver Uriel - CEO, Capital Cell
  • Panelist Richard Seabrook - Senior Advisor, Wellcome Trust

16:00 17:00 (60 mins)

Main agenda

Key considerations in microbiome partnering

Location: Level 1, Room 123

The human microbiome is garnering research interest across the globe and industry is responding to the growing possibilities of therapeutic developments in a variety of ways, a key aspect of which is partnerships. The current state of play means emerging companies are often looking for specific expertise or experience in their partners, often influenced by the variety of approaches under different regulatory jurisdictions or financial structures. Join this panel to hear how emerging microbiome companies identity their preferred partners and what pharma companies and funders are able to bring to the table.

  • Moderator Mike Ward - Global Director of Content, Informa Pharma Insights
  • Panelist Xavier Aldeguer Mauté - Co-founder and Medical Advisor, Goodgut
  • Panelist Michel de Baar - Executive Director, BD&L, Infectious Diseases & Vaccines, Cardiovascular & Metabolic Diseases, MSD
  • Panelist Eric de La Fortelle - Venture Partner, Seventure

17:15 18:15 (60 mins)

Main agenda

Making early investment decisions: Incorporating flexibility into your R&D strategy

Location: Level 1, Room 123

Strategic decisions made during the earliest stages of clinical development often have an unseen impact on the downstream commercial potential of an asset. This is true for both large pharma and emerging biotech companies. What choices must be made during early clinical development? What are the trade-offs to consider? And, how do these key decisions affect the commercial potential, partnering opportunities, and a company’s ability to invest in other assets in a therapeutic franchise or overall pipeline? Do the questions and answers differ for a platform versus a product company? We will address these and others questions as we further unpack the concept of incorporating flexibility into your R&D strategy.

  • Moderator Philip Kenner - Principal, ClearView Healthcare Partners
  • Panelist Magnus Björsne - CEO, AZ BioVentureHub AB
  • Panelist Michael Henderson - VP, Asset Acquisition, Strategy, and Operations, BridgeBio
  • Panelist Philippe Lopes-Fernandes - Senior VP, Head of Global Licensing and Business Development, Merck
  • Panelist James Sapirstein - CEO, ContraVir Pharmaceuticals

13:30 14:30 (60 mins)

Main agenda

The business of rare disease company development

Location: Level 1, Room 121

What structures and strategies does a company need to develop in order to thrive as a company targeting rare diseases? Does the rarified space of rare diseases mean that companies need to take different financing considerations, partnering models, or post-approval hurdles into consideration? Does the very specificity of orphan drug development mean that the companies created to find cures and treatments mirror that same singularity, rendering them difficult to partner with, buy or achieve another kind of exit? These and other questions will be discussed in this session about the business of developing companies around rare disease therapeutics.

  • Moderator Alison Silva - CEO and President, Critical Outcome Technologies
  • Panelist Timothy Cote - Principal and CEO, Coté Orphan
  • Panelist Michael Pistone - Director of Marketing, Innovation and Commercialization, Cincinnati Children's Hospital
  • Panelist Wendy White - Chair, Global Genes

14:45 15:45 (60 mins)

Main agenda

The immuno-oncology universe

Location: Level 1, Room 121

The pace of activity around the approvals and development of Immuno-Oncology (IO) agents in just the past five years has been quite astounding. Maybe a better word is daunting, a bit like The Wizard of Oz: “Lions, and tigers and bears, oh my!” BioPharma large and small alike face the quandary of an almost embarrassment of options, making early stage go/no go and clinical development path decisions, layering on regulatory and commerical considerations, all exceedingly complex and challenging in their own right, let alone in this dynamic and rapidly evolving space. So, let’s pause, breathe, and step back a moment. Let’s consider what these different MOAs and modalities bring to patients. Is the industry going about studying the combinations in the most relevant manner? What does each target and platform provide that is unique to a specific cancer or patient type? Are there aspects of the immune system we are neglecting? Are there cancers we are neglecting? It seems that we are perhaps short-sightedly relegating many previously hot oncology targets like oncogenes to the backburner—is this true, and is this appropriate? This session will endeavor to break out of the usual rhetoric around the IO field to pressure test in real-time some of its evolving and newly sacred assumptions.

  • Moderator Jeffrey Bockman - VP, Defined Health
  • Panelist Pamela Esposito - CBO, Replimune
  • Panelist John Haurum - CEO, F-star
  • Panelist Christophe Quéva - CSO, iTeos Therapeutics
  • Panelist Alan Wise - CEO, IOmet Pharma/MSD

16:00 17:00 (60 mins)

Main agenda

Valuing curative and durable response therapies

Location: Level 1, Room 121

Taking a back seat in the noisy and increasingly rancorous discussion about drug prices is how the increasing personalization of therapeutics may change the game. As advances in biology inevitably lead us to a future where individualized therapeutic approaches assume a more prominent role, biopharma’s already challenged commercial model (which for the most part remain stuck in a world of “off the shelf” products used chronically) will need to respond or face a clear threat to continued innovation. For example, there are presently well over 200 gene therapy programs in Phase II development, and at least some are likely to reach the market before key questions about how to value these potentially curative products are addressed. This issue extends to “conventional” products, as well, such as in cancer where ultra-expensive new immunotherapies typically used in combinations are beginning to generate durable responses, but at a recurring cost that is widely seen as unaffordable. This panel will address the challenges in designing a new biopharma business model that remains relevant in a world otherwise ready to welcome transformational new therapies.

  • Moderator Ed Saltzman - President, Defined Health
  • Panelist Joe Dupere - CEO, Rexgenero
  • Panelist John McDonald - VP, Business Development and External Innovation, Biogen
  • Panelist Georges Rawadi - VP Business Development and IP, Celyad
  • Panelist Thomas Zioncheck - Global Head, Business Development for Neuroscience, Ophthalmology, and Research Tools and Technologies, Genentech

17:15 18:15 (60 mins)

Main agenda

Commercializing cell and gene therapies

Location: Level 1, Room 121

New business models for clinical development and manufacturing require strategic partnerships among researchers, manufacturers and payers to fully realize the commercial opportunities.

  • Moderator Morrie Ruffin - Managing Partner, Adjuvant Partners
  • Panelist Boro Dropulic - Chief Science Officer and General Manager, Lentigen Technology Inc., A Miltenyi Biotec Company
  • Panelist Miguel Mulet - Director, Strategy and New Projects, TiGenix NV
  • Panelist Peter Nell - VP, Head Strategy and Business Development, Casebia Therapeutics

13:30 17:30 (240 mins)

Main agenda

Pharma Company Presentations

Location: Level 1, Room 119

Hear the latest partnering opportunities from global pharma companies

13:30 – Boehringer Ingelheim – Bernd Nosse, Global Head BD&L Technologies

13:45 – Amgen – Olaf Koenig, Director Business Development

14:00 – MSD – Reza Halse, President, MRL Venture Fund

14:15 – Bristol-Myers Squibb – Paul Biondi, Senior VP, Head of Business Development

14:30 – AbbVie – Adam Houghton, Senior Director and Head, Immunology Search and Evaluation

14:45 – Johnson & Johnson Innovation – Phillipe Alen, Senior Director, Business Development,

15:00 – Roche – Fang Ni, Director, Oncology Business Development and Licensing

15:15 – Genentech – Visali Ramanathan, Manager Immunology and Infectious Disease, Business Development

15:30 – Eli Lilly and Company – Johnston Erwin, VP, Corporate Business Development

15:45 – Sanofi – Sarah Holland, VP, BD&L Business Partner, General Medicines and Emerging Markets

16:00 – Merck – Philippe Lopes-Fernandes, Senior VP, Head, Global Business Development and Alliance Management

16:15 – Purdue Pharma – David Saussy, Executive Director, Scientific Evaluation, Licensing and Business Development

16:30 – Bayer – Dmitrij Hristodorov, Director Early Licensing

16:45 – Novartis  Begoña Carreño, Global BD&L Head Respiratory

17:00 – Servier – Michel Sestier, Project Director BD&L in Oncology and Rheumatology

17:15 – Pfizer – James Eshelby, Executive Director, External R&D Innovation


16:05 16:25 (20 mins)

Main agenda

Break and Breathe

Location: Level 1, Room 127

Enhance your conference experience by using simple breathing techniques, movement and light stretches in order to charge your body and mind for better decision making and more energy throughout the day. The breath is a source of life. By practicing special breathing techniques, we can fight diseases, stimulate the endocrine and autonomic nervous systems and purify the blood. These breathing techniques are designed to make the body fit and to handle stress in everyday life. Open to all. No prerequisites required. Standing and seated (chair) positions only.

16:35 16:55 (20 mins)

Main agenda

Break and Breathe

Location:  Level 1, Room 127

Enhance your conference experience by using simple breathing techniques, movement and light stretches in order to charge your body and mind for better decision making and more energy throughout the day. The breath is a source of life. By practicing special breathing techniques, we can fight diseases, stimulate the endocrine and autonomic nervous systems and purify the blood. These breathing techniques are designed to make the body fit and to handle stress in everyday life. Open to all. No prerequisites required. Standing and seated (chair) positions only.

17:45 18:45 (60 mins)

Main agenda

Champagne reception

Level 0, Exhibit Hall, Booth 61

19:00 21:30 (150 mins)

Main agenda

Evening Networking Reception with Buffet-style dinner

Location: Museu Nacional d'Art de Catalunya (MNAC) | National Museum of Art Catalonia (MNAC), 

Parc de Montjuïc, 

08038, Barcelona | (map)

The Museu Nacional d’Art de Catalunya (MNAC) is located in the Palau Nacional (National Palace) of Montjuïc, and was constructed for the International Exposition of 1929. In 1934 it opened its doors as the Museu d'Art de Catalunya, bringing together the medieval collection. It hosts the best collection of Romanesque mural painting in the world and the most representative artists of Catalan Modernism, such as Gaudí and Casas. Gothic art, great European Renaissance and Baroque painters, for example Tiziano or Velázquez, and the collection of photography, complete the collection. Due to its location and outstanding architecture it is an exciting venue for social and cultural events which allows a breathtaking view over Barcelona.

SHUTTLE BUSES:

18:30–19:00 Shuttle buses depart from the conference center to the evening event.

21:00–22:00 Shuttle buses depart from the evening event to all conference hotels.